HCW9302 is an investigational, first-in-kind interleukin-2 fusion immunotherapeutic candidate from HCW Biologics for autoimmune and inflammatory diseases. It entered first-in-human clinical testing in alopecia areata in 2025. The program is focused on expanding regulatory T-cell activity to reduce pathological inflammation.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
HCW Biologics and WY Biotech closed first-round financing for joint venture Trimmune, granting exclusive worldwide license to develop preclinical TRBC molecule HCW11-006 for $7 million in upfront consideration, with Phase 1 trial planned in China for first half of 2027.
